Європейський Союз - хорватська - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - virus pds 2242 virus / virus vcp1529 / vcp1533 virus / vcp3011 - imunomodulatori, žive virusne vakcine virusa influence konja - konji - aktivna imunizacija konja od četiri mjeseca ili starije od konjske gripe radi smanjenja kliničkih znakova i izlučivanja virusa nakon infekcije.

Європейський Союз - хорватська - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - tetani клостридия virus анатоксин / pds 2242 virus / virus vcp1529 / vcp1533 virus / vcp3011 - immunologicals for equidae, live viral and inactivated bacterial vaccines, equine influenza virus + clostridium - konji - aktivna imunizacija konja od četiri mjeseca ili starije od konjske gripe radi smanjenja kliničkih znakova i izlučivanja virusa nakon infekcije i protiv tetanusa radi sprječavanja smrtnosti.

Європейський Союз - хорватська - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - virus mačje leukemije rekombinantnog kanarinaca (vcp97) - imunomodulatori za mačke, - mačke - aktivna imunizacija mačaka starijih od 8 tjedana protiv mačje leukemije radi sprečavanja perzistirajuće viremije i kliničkih znakova povezane bolesti. otkrivanje imuniteta pokazalo se 2 tjedna nakon primarnog cijepljenja. trajanje imuniteta je jedna godina nakon posljednjeg cijepljenja.

Європейський Союз - хорватська - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Європейський Союз - хорватська - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Європейський Союз - хорватська - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Європейський Союз - хорватська - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. pokusi imuniteta pokazani su tjedan dana nakon primarnog cijepljenja za rhinotracheitis, kalicivirus, chlamydophila felis i panleucopenia komponente. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Європейський Союз - хорватська - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Європейський Союз - хорватська - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - Рекомбинантный герпесвирус turske, procijediti vhvt013-69, živjeti - imunomodulatori za ptice, domaće peradi, imunomodulatori - embryonated eggs; chicken - za aktivna imunizacija pilića:za sprečavanje smrtnosti i smanjenje kliničkih znakova i poraza zaraznih bolesti Бурсальной . smanjiti smrtnost, klinički znakovi i poraza bolest Марека .

Європейський Союз - хорватська - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - afatinib - karcinom, ne-malih stanica pluća - antineoplastična sredstva - giotrif u monoterapiji namijenjen za liječenje ofepidermal ako uređaj primatelja faktor rasta (РЭФР) тки-naivnih odraslih pacijenata sa lokalno-uobičajena ili metastatskih немелкоклеточным raka pluća (НМРЛ) koja aktivira mutacije РЭФР (- s);lokalno-uobičajena ili metastatskih НМРЛ pločastih stanica гистологии napreduje ili nakon kemoterapije платиносодержащей.